Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP656042.RAAtHXoW7k61pbuqNgnQ8sOJQ3KmjsfTRaQgksbFfOpys130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP656042.RAAtHXoW7k61pbuqNgnQ8sOJQ3KmjsfTRaQgksbFfOpys130_provenance.
• NP565620.RAd8GDAjgk_zw8uJVXj4pUAy0bGrBgRNk7I7wgzBMhNGw130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP565620.RAd8GDAjgk_zw8uJVXj4pUAy0bGrBgRNk7I7wgzBMhNGw130_provenance.
• NP518611.RAvR4DiuvBIJC8ynTocPhJCbMmmW3OkmOaDIEszjpMznI130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP518611.RAvR4DiuvBIJC8ynTocPhJCbMmmW3OkmOaDIEszjpMznI130_provenance.
• NP718726.RAAtzoDEiZBj10orL5X0kM_lR_SA1PXSbylokm23z401o130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718726.RAAtzoDEiZBj10orL5X0kM_lR_SA1PXSbylokm23z401o130_provenance.
• assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP919054.RAVltRwOC5Uw9lDEI-zXhaZ6Bs6LwTb991-Kpi9mwfgVU130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP919054.RAVltRwOC5Uw9lDEI-zXhaZ6Bs6LwTb991-Kpi9mwfgVU130_provenance.
• NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_provenance.
• NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594601.RAVI3aC04FE71BZLP4AZWqxGS8YwURo1mWXMHlbtRQvGI130_provenance.
• NP594607.RAdRcKbjSMY_vRfg8bk8x_2diMzD_l1KEnx4VCrv3KnVA130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594607.RAdRcKbjSMY_vRfg8bk8x_2diMzD_l1KEnx4VCrv3KnVA130_provenance.
• NP384454.RAn1e-tfQr08bRMB5zrCfjooOdBe7SFByr1BH2ZXuQw-M130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP384454.RAn1e-tfQr08bRMB5zrCfjooOdBe7SFByr1BH2ZXuQw-M130_provenance.
• NP844446.RACzHcTbLwH04g39mn3xToeFeItWo52Jnh6xOt3TcxLik130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP844446.RACzHcTbLwH04g39mn3xToeFeItWo52Jnh6xOt3TcxLik130_provenance.
• NP594605.RAuTfrFFUKDtHwqwX_R9NXommDn73BN17gRlUr-zkbG1Y130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594605.RAuTfrFFUKDtHwqwX_R9NXommDn73BN17gRlUr-zkbG1Y130_provenance.
• NP594608.RAittSgpi9YYrnw9stgq1ksoe79ccISTmGHGADFWZXs8s130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594608.RAittSgpi9YYrnw9stgq1ksoe79ccISTmGHGADFWZXs8s130_provenance.
• NP594604.RAHIJWcMce5hwGVqsdpG0OTmnTUb2dt8qvehySzttRYik130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594604.RAHIJWcMce5hwGVqsdpG0OTmnTUb2dt8qvehySzttRYik130_provenance.
• NP594606.RAIvaA0j9mirWlWOhXuR7bR3EARb7Ywg7X7LwfkI20zxU130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594606.RAIvaA0j9mirWlWOhXuR7bR3EARb7Ywg7X7LwfkI20zxU130_provenance.
• NP594600.RAx3VIHE9UC3kj_muXNrak3CDyJlpihe26-brzqN0i6OA130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP594600.RAx3VIHE9UC3kj_muXNrak3CDyJlpihe26-brzqN0i6OA130_provenance.
• NP919033.RA1itkvZZv6zXo2Ko2xSJJ85L32ztDmAoyAj-179yE7Kk130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP919033.RA1itkvZZv6zXo2Ko2xSJJ85L32ztDmAoyAj-179yE7Kk130_provenance.